相关实验视频

Updated: Feb 28, 2026

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy

Published on: January 31, 2025

在分散型大B细胞淋巴瘤 (DLBCL) 中的脂质代谢重编程:机制和治疗策略

Yue-E Ding^1,2,3,4, Yi-Ran Zhong^2,3,4, Lai-Shun Zhang¹

¹Department of Pharmacy, Zhongshan City People's Hospital, Zhongshan 528403, China.

|February 27, 2026

概括

扩散性大B细胞淋巴瘤 (DLBCL) 涉及多种不同的亚型,影响治疗. 脂质代谢,细胞死亡和瘤免疫微环境极大地影响DLBCL的进展和治疗耐药性.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
免疫学免疫学免疫学

背景情况:

扩散性大B细胞淋巴瘤 (DLBCL) 是一种异质的非霍奇金淋巴瘤,具有明显的分子亚型 (GCB,ABC,PMBL).
尽管R-CHOP治疗,大约40%的DLBCL患者面临复发或耐药性疾病.
DLBCL细胞增殖依赖于复杂的脂质代谢调节网络.

研究的目的:

审查了解DLBCL分子机制的最新进展.
探索DLBCL中的脂质代谢,细胞死亡 (如铁亡) 和瘤免疫微环境 (TIME) 之间的相互作用.
讨论预后生物标志物的临床相关性,以开发精确疗法.

主要方法:

关于DLBCL近期科学进展的文献综述.
推动DLBCL进展和治疗耐药性的分子机制的分析.
检查脂质代谢,铁和时间在DLBCL病变发生中的作用.

主要成果:

在DLBCL亚型中存在显著的分子异质性,影响遗传特征和临床结果.
脂质代谢,铁和时间是DLBCL恶性进展的关键调节者.
这些相互关联的过程显著影响DLBCL的耐处理性.

结论:

了解脂质代谢,细胞死亡和时间的相互作用对于DLBCL治疗至关重要.
识别与这些途径相关的预后生物标志物可以指导精确治疗的开发.
针对这些机制的新治疗策略有望改善DLBCL患者的治疗结果.

关键词:

扩散大的B细胞淋巴瘤.铁性化 (ferroptosis) 是一种脂质新陈代谢重编程的重编程预后生物标志物预后生物标志物针对性药物针对性药物治疗策略治疗策略瘤免疫的微环境

更多相关视频

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies

Published on: September 13, 2024

相关概念视频

Overview of Lipid Metabolism

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...